Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Major Depressive Disorder (CLARITY)
Status:
Completed
Trial end date:
2018-10-01
Target enrollment:
Participant gender:
Summary
To assess the efficacy of pimavanserin compared to placebo when given adjunctively to a
selective serotonin reuptake inhibitor (SSRI)/serotonin-norepinephrine reuptake inhibitor
(SNRI) antidepressant as treatment of patients with Major Depressive Disorder (MDD) and an
inadequate response to antidepressant therapy